An Open-Label, Multiple Simon 2-Stage Study of INCB039110 Administered Orally to Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) or Post Essential Thrombocythemia Myelofibrosis (PET-MF)

Trial Profile

An Open-Label, Multiple Simon 2-Stage Study of INCB039110 Administered Orally to Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) or Post Essential Thrombocythemia Myelofibrosis (PET-MF)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Itacitinib (Primary)
  • Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
  • Focus Therapeutic Use
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 09 Dec 2014 Primary analysis results presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.
    • 12 Mar 2014 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.
    • 10 Dec 2013 Interim results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top